Can a cancer drug cure a rare nerve disease? new study aims to find out
NCT ID NCT04480450
First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 22 times
Summary
This study tested whether rituximab, a drug that depletes certain immune cells, could help people with chronic inflammatory demyelinating polyneuropathy (CIDP) stop their current medications and achieve long-term remission. The study planned to enroll 48 adults with CIDP across three subgroups. However, the study was withdrawn before any participants were enrolled, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.